Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This is from Inaco on other board , please cane someone post next link to conference?
From other side
a week away from the next conference
lets hope any update gets an RNS
have we heard about the proposed Doublet in renal ? that was about 10 weeks ago from interims
Modi-1 to be assessed in renal cell carcinoma in combination with double CPI therapy in the ModiFY study pending protocol amendment by the MHRA
I don’t think we’ve heard anything on ModifY since July 2023, 9 months ago, so hoping for something soon. However, these conference presentations don’t seem to contain anything new so I won’t get my hopes up, but I would be delighted to be proved wrong.
Agree Green it would be good to get an official update on the 2 main trial programmes so that we can at least be kept informed,
This would represent the 5th Meeting/ conference presentation in 6 weeks so you would have thought there must be something new to update us all on.
Just found out what should be a very interesting presentation but is a long way off.
Thursday 31st Oct at WVC ( Europe) at 1115
LD presenting on Clinical update on the DC targeting melanoma a Vax SCIB1 and the Modi 1 Vaccine targeting citrullination.
Can’t post link as it came direct to me and can’t share.
Ivy she did the same conference last year on 17 Oct with exactly the same title.
Sorry 19th October 2023
thanks fd for that and i recall that she has been “ copied” previously but the below was on the 2024 draft agenda which was sent direct to me.
if wvc are fleshing out the 24 agenda by rehashing previous agendas then that is not good form but i have no reason to doubt it.
bit more detail to my lse post sorry can’t post link
& therapeutic vaccines
chair:
09:30
new frontiers in cancer vaccine antigens: ai-driven target discovery for broader therapeutic
reach
senior representative, evaxion biotech a/s
09:45 navigating the complex study designs of therapeutic vaccines
senior representative, ppd, part of thermo fisher scientific
10:00
10:15
personalized vaccine tg4050 induces polyepitopic immune responses against private neoantigens
in resected hpv negative head and neck cancers
to invite: dr alessandro riva, ceo, transgene
10:30 neoantigen directed cell therapies
dr sergio quezada, chief scientific officer, achilles therapeutics - tbc
10:45 camyo-01: colorectal cancer-specific camyotypes formulated into an mrna vaccine
cedric bogaert, co-founder and ceo, myneo therapeutics
11:00 phase ii uv1 trial updates
to invite: carlos de sousa, ceo, ultimovacs
11:15
clinical update on the dc targeting melanoma vaccine, scib1 and the modi-1 vaccine targeting
citrullination
prof lindy durrant, ceo & cso, scancell
11:30-12:30 expo & partnering break
join us in the exhibition hall for: 1-2-1 partnering & poster sessions
12:30
targeting mkras vaccination to the lymph nodes to promote anti-tumor immunity: preliminary
results from the phase 1 amplify-201 trial
robert connelly, ceo / dr pete demuth, cso, elicio therapeutics
12:45
nous-209 genetic vaccine encoding shared neoantigens for treatment and interception of msi
tumors
dr elisa sc****lli, cso / dr morena d’alise, vp of immunology, nouscom
13:00
neoantigen immunotherapy for solid tumors: molecular responses and clinical benefit in end-
stage patients – title tbc
dr andrew allen, ceo, gritstone bio
13:15 from covid-19 to oncology: regulatory perspectives on the development of rna vaccines
senior representative, biontech - tbc
13:30 mrna-4157 individualized neoantigen therapy: mrna therapeutics coming of age in cancer
senior representative, moderna – tbc
13:45 panel: tbc
cedric bogaert, co-founder and ceo, myneo therapeutics
klaus orlinger, cso / henning lauterbach, vp, head of discovery and translational medicine,
hookipa pharma - tbc
andrew allen, ceo / karin jooss, evp & head of r&d, gritstone bio
senior representative, biontech
senior representative, moderna
This conference is in Scancell's Q4 so just maybe we will have long awaited trial updates either before or the day after Lindy presents.
Lindy's presentation is followed by
"11:30-12:30 expo & partnering break"
in which Lindy will no doubt secure 2 massive deals 😂